Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

9.515 +2.085 (+28.06%)

Streaming Delayed Price Updated: 10:09 AM EST, Feb 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Which stocks are moving before the opening bell on Tuesday? ↗

Today 8:30 EST

Via Chartmill

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

Today 8:02 EST

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗

February 23, 2026

The company said its current resources are expected to fund operations into the second quarter of 2028.

Via Stocktwits

Topics Earnings

Vir Biotechnology (VIR) Earnings Call Transcript ↗

February 23, 2026

Vir Biotechnology (VIR) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗

February 23, 2026

Via Chartmill

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 09, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

December 16, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

This hot biotech stock could have a lot more room to run.

Via The Motley Fool

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

November 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 05, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

November 03, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

October 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD’s The Liver Meeting® 2025

October 07, 2025

From Vir Biotechnology, Inc.

Via Business Wire

This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

August 29, 2025

Via Benzinga

This Southwest Gas Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday ↗

August 29, 2025

Via Benzinga

This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

August 28, 2025

Via Benzinga

This Guess Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗

August 28, 2025

Via Benzinga

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday ↗

August 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 27, 2025

Via Benzinga

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

August 25, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir (VIR) Q2 Revenue Drops 61% ↗

August 07, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.